The bioavailability of polyphenols in human and rodents has been discussed regarding their biological activity. We found different metabolite profiles of quercetin in rat plasma between two administration procedures. A single intragastric administration (50 mg/kg) resulted in the appearance of a variety of metabolites in the plasma, whereas only a major fraction was detected by free access (1% quercetin). The methylated/non-methylated metabolites ratio was much higher in the free access group. Mass spectrometric analyses showed that the fraction from free access contained highly conjugated quercetin metabolites such as sulfo-glucuronides of quercetin and methylquercetin. The metabolite profile of human plasma after an intake of onion was similar to that with intragastric administration in rats. In vitro oxidation of human low-density lipoprotein showed that methylation of the catechol moiety of quercetin significantly attenuated the antioxidative activity. These results might provide information about the bioavailability of quercetin when conducting animal experiments.
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Flavonoids are widely distributed in plant foods and beverages, and are therefore regularly ingested with the human diet. Quercetin (3, 3 0 ,4 0 ,5,7-pentahydroxyflavone) is a prime example of such a flavonoid found in broccoli, apple, and especially, in onions, as the glycosidic form. 1) Epidemiological evidence has shown that a diet rich in quercetin decreased the incidence of cardiovascular and neoplastic diseases. [2] [3] [4] [5] [6] [7] The beneficial health effects of quercetin and other flavonoids have been investigated in relation to their antioxidative activities in vivo. The antioxidative potential of flavonoids is related to the number and position of the free hydroxyl groups in the molecule. 8) Upon ingestion, flavonoid glycosides are rapidly hydrolyzed during passage across the small intestine or by bacterial activity in the colon to generate the aglycone(s), which is further metabolized into the glucuronidated, and/or sulfated form. Alternatively, the 3 0 -or 4 0 -hydroxyl group in the B-ring catechol moiety can also be methylated by catechol-O-methyltransferase (COMT) activity. Therefore, the regioselectivity of conjugation of the hydroxyl groups can be expected to modulate the biological activity of quercetin. It have been reported that quercetin-3-glucuronide (Q3GA) and quercetin-3 0 -sulfate were the major quercetin conjugates in rat and human plasma, in which no aglycone could be detected. 9, 10) The physiologically conceivable activities of various quercetin metabolites have been reported.
11)
Although we have examined the bioavailability of a quercetin intake by rabbits, 12) rats, 13, 14) mice, 15) and humans, [16] [17] [18] the relative contribution of different types of conjugates to the biological activity in vivo has not yet been clarified. It is expected that the B-ring catechol moiety of flavonoids represents the radical scavenging action of the metabolites in vitro. 10, 18) We found in this study that the metabolite profiles and antioxidative capacity in the plasma of rats were significantly affected by the administration procedure. Our results might provide helpful information on flavonoid studies for designing in vivo experiments on rodents and humans and perhaps for understanding the precise mechanism for the biological activity of flavonoid metabolites in vivo.
Materials and Methods
Chemicals. Quercetin dihydrate was purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). Isorhamnetin (3 0 -methyl quercetin) was obtained from Extrasynthese (Genay, France). Quercetin-3-O--Dglucuronide (Q3GA) was chemically synthesized as previously reported.
10)
Animals. Male CD (SD) rats (220-250 g, 8 weeks old; Charles River Japan, Yokohama, Japan) were housed in a controlled room (temperature, 23 AE 1 C; humidity, 45-50%; light-dark cycle, 12 h each; lights on, 8 am). The rats were given free access to laboratory feed (MF; Oriental Yeast Co., Tokyo, Japan) and tap water for one week before their use in the experiments. Although a trace amount of quercetin glycoside(s) was detected in the MF diet (22:7 AE 0:9 ng/g, n ¼ 3), we confirmed similar results when a purified (non-flavonoid) diet was utilized (data not shown). This study was performed according to the guidelines for the care and use of laboratory animals of The University of Tokushima Graduate School, Institute of Health Biosciences. All efforts were made to minimize animal suffering and to reduce the number of animals used.
Administration of quercetin to the rats. For intragastric administration, the rats (n ¼ 6 for each group) were starved overnight and then given quercetin (50 mg/kg of body weight) dissolved in 1 ml of propylene glycol by using an oral Zonde needle connected to a 1-ml syringe. Control groups (n ¼ 6) were given propylene glycol alone. After 30 min or 1 h, the rats were sacrificed by decapitation, blood samples were collected into heparinized tubes, and the plasma was obtained by centrifugation. For a free access experiment, the rats were given free access to the MF diet containing 1% (w/w) quercetin for four weeks until scarification. The average intake of the diet was 21.3 g (i.e., 213 mg of quercetin). The plasma was obtained from the heparinized blood collected by decapitation.
Human plasma after the intake of quercetin. Healthy volunteers (n ¼ 4), who provided informed consent, were fasted overnight and then served 350-500 g of cooked onion paste (provided by Kagome Research Institute, Tochigi, Japan) roasted with salad oil. The volunteers ate the onion paste with a spoon at their own pace (for 15-30 min). The onion amounts were set to be almost the same per body weight (approximately 7 g/kg). The quercetin content in the onion paste was 32.9 mg/100 g of onion paste (as the equivalent for the quercetin aglycone). Before and 1.5 h after intake, heparinized blood (about 8 ml) was collected from each subject, and the plasma was obtained by centrifugation. The protocol was approved by the Ethical Committee of the University of Tokushima, Japan.
Analysis of quercetin metabolites in the plasma. The quercetin metabolites in the plasma (rat plasma, 50 ml; human plasma, 200 ml) were extracted with five volume of methanol, and each methanolic fraction was evaporated under an N 2 stream. The extract was dissolved in 50 ml of 15% aqueous acetonitrile containing 0.5% phosphoric acid. Twenty ml of the sample was injected into an HPLC-UV detection system (JASCO Gulliver 900-series, JASCO Corporation, Tokyo, Japan) equipped with a Cadenza CD-C18 (3 Â 100 mm, Imtakt Corporation, Kyoto, Japan; condition I) or a TSK gel ODS-80Ts column (4:6 Â 150 mm, Tosoh, Tokyo, Japan; condition II). Condition II was used for the analysis of the human plasma. The separation of the compounds was carried out by gradient elution. Solvent A was 0.5% phosphoric acid, and solvent B was 100% acetonitrile. The gradient program was as follows: 0-2 min, 15% B; 2-22 min, linear gradient to 40% B; 22-24 min, 40% B hold; 24-32 min, linear gradient to 15% B; flow rate, 0.45 ml/min (for condition I) or 0.8 ml/min (for condition II). UV detection was performed at 370 nm.
The total content of quercetin derivatives in the plasma was measured by HPLC after a -glucuronidase/sulfatase treatment. Briefly, 50 ml of a plasma sample was mixed with 25 ml of 2 mg/ml of sulfatase H-1 (from Helix Pomatia, 14 units of sulfatase and 300 units of -glucuronidase activity/mg of enzyme) in a 50 mM sodium phosphate buffer (pH 5.0) and incubated at 37 C for 2 h. The released quercetin/methylquercetins were extracted and analyzed as already described.
Fraction X was collected from the injection of a 50-ml plasma sample by using HPLC condition I as already described. After evaporation, the fraction was dissolved in 50% aqueous acetonitrile and then analyzed by mass spectrometry.
Mass spectrometry. Mass spectrometric characterization of the quercetin metabolites was performed by an infusion analysis, using an Esquire 2000T ion-trap tandem mass spectrometer (Bruker Daltonics Inc., Billerica, MA, USA) in the negative ionization mode at a flow rate of 500 ml/h. Collision-induced dissociation experiments coupled with multiple tandem mass spectrometry MS n employed helium as the collision gas. The MS conditions were as follows: nebulizer gas (N 2 ), 10 psi; dry gas (N 2 ), 4 l/min; dry temperature, 250 C; capillary voltage, 4000 V.
Cell culture. Bovine aortic endothelial cells (BAECs) 19) were cultured in Medium 199 (Sigma) containing 20% fetal bovine serum, 100 mg/ml of penicillin, and 100 units/ml of streptomycin in an atmosphere containing 5% CO 2 at 37 C.
LDL oxidation. LDL (d ¼ 1:063{1:093 g/ml) was isolated from healthy human volunteers by sequential ultracentrifugation and then dialyzed in phosphate-buffered saline (PBS). This method could give the purified LDL fraction exhibiting one major protein band for apolipoprotein B-100 by agarose electrophoresis (data not shown). The LDL concentration was determined by measuring the protein content with a BCA protein assay kit (Pierce). For cell-free oxidation, LDL (0.2 mg/ml in PBS) was incubated in the presence of 10-20 mM Cu 2þ at 37 C. For cell-mediated oxidation, BAECs in a 60-mm dish were treated with LDL (200 mg/ml in FBS-free Medium 199) in the presence of 5 mM Cu 2þ at 37 C. After incubating, the oxidation reaction was terminated by adding 0.1 volume of 1 mM ethylenediamine tetraacetic acid/10 mM 2,6-di-tert-butyl-p-cresol solution. The LDL oxidation was measured as thiobarbituric acid-reactive substances (TBARS) with fluorescent detection (excitation at 515 nm, emission at 553 nm). Tetraethoxypropane was used as the standard compound that readily decomposed into TBA-reactive malondialdehyde, a representative aldehyde formed in oxidized LDL, during the assay process. To evaluate the inhibitory effect of the quercetin metabolites on LDL oxidation, authentic quercetin derivatives or the rat plasma extract were added to the reaction mixture. The rat plasma metabolites were extracted as described for the HPLC samples and then dissolved in PBS (the same volume as that of the starting plasma).
Results

HPLC profiles for the quercetin metabolites in rat plasma from two administration procedures
When the plasma samples from the rats intragastrically given quercetin (50 mg/kg) were analyzed by HPLC, many peaks indicating quercetin metabolites were detected (Fig. 1A, top) . The major peak eluted at 8 min was identified as quercetin-3-glucuronide (Q3GA) by comparing with an authentic standard (data not shown). Quercetin aglycone (20.5 min) and methylquercetin(s) (3 0 -or 4 0 -, 27 min) were also detected as smaller peaks. Similar metabolite profiles were obtained from all the plasma samples of rats that had been intragastrically given quercetin. These non-conjugated quercetins (aglycone and methylated forms) have been detected before in rat plasma, 20) but not in human plasma. 9) Several studies have attempted to identify the quercetin metabolites of rat plasma from intragastric administration. 10, 20) Based on these reports and the enzymatic hydrolysis experiments using -glucuronidase/sulfatase, we presumed the metabolite pattern including glucuronides, di-glucuronides, sulfates, and sulfo-glucuronides as indicated in Fig. 1A , top. The presence of these speculated metabolites was confirmed by HPLC-tandem mass spectrometry (Kawai et al., unpublished results). On the other hand, it is of interest that only a broad fraction (Fraction X) could be detected in the plasma of rats given free access (Fig. 1A, bottom) , in which Q3GA could not be detected. Similar metabolite profiles were also obtained from all the plasma samples of rats fed for 1 week (data not shown) or 2 weeks (Fig. 1A, lower  inset) . Although trace amounts of Q3GA were detected in some samples from free access (see Fig. 1A , lower inset), they were only below 1% of the total metabolites (data not shown). No time-dependent change in the profiles was apparent at least between 1 week and 4 weeks. To clarify the difference in the biological activities of the metabolites between the two procedures, we first examined the extent of methylation in the metabolites by analyzing quercetin and methylated quercetin after treating the plasma with -glucuronidase/sulfatase. As shown in Fig. 1B , the proportion of methylated metabolites was much higher in the free access group (intragastric ratio = 0.39 vs. free access ratio = 3.79). The total quercetin concentration (quercetin + methylated quercetin) was also higher in the free access group (intragastric-2.5 mM vs. free access-7.0 mM).
Mass spectrometric characterization of Fraction X To determine the metabolites constituting Fraction X, the fraction was collected and then analyzed by electrospray ionization ion-trap tandem mass spectrometry. Figure 2A shows the mass spectrum of the fraction, indicating that m=z 571.1, 557.1, and 395.1 were the major molecular ions of the fraction. These molecular ions might indicate methylquercetin-sulfoglucuronides (m=z 571.1), quercetin-sulfoglucuronides (m=z 557.1), and methylquercetin-sulfates (m=z 395.1). Although we confirmed that no fragmentation of the glucuronic acid moiety of Q3GA took place under the same conditions (data not shown), there might be a possibility that m=z 395 was a fragment ion of m=z 571.1. To confirm this speculation, MS 2 and MS 3 data were then measured (Fig. 2B) 
Structure-antioxidative activity relationship
As shown in Fig. 1 , the metabolites were much more methylated in the free access group. In general, the antioxidative activity of quercetin is thought to be substantially due to its catechol moiety. 10) To confirm the structure-antioxidative activity relationship for the quercetin metabolites, the inhibitory effects of a quercetin-3-glycoside (glucoside, Q3G) and 3 0 -methylquercetin (isorhamnetin) on LDL oxidation were compared. The chemical structures of these two types of quercetin derivative are shown in Fig. 3A . Two procedures for the LDL oxidation reaction were performed: cell-free, copper ion-induced oxidation (Fig. 3B) and endothelial cell-mediated oxidation (Fig. 3C) . The copper ion is more frequently used for LDL oxidation in vitro because it alone, without chelating agents, can initiate the lipid peroxidation chain reaction in LDL. 21) In addition, LDL oxidation mediated by endothelial, smooth muscle, and monocyte/macrophage cells is thought to feature in vivo LDL oxidation. 22) Q3G inhibited dose-dependently both cell-free and cell-mediated LDL oxidation, whereas the inhibitory effect of 3 0 -methylquercetin was quite weak in both systems. These results showthat the free antioxidative potential of quercetin required its free catechol moiety. Furthermore, 3
0 -methylquercetin-3-glucoside did not inhibit LDL oxidation at all, even at 10 mM, 18) showing that the conjugation of multiple positions significantly attenuated the antioxidative activity. Similar results have also been reported when using the rat plasma glucuronides, Q3GA and Q4 0 GA. 10, 18) Antioxidative activity of the rat plasma metabolites To examine the biological consequences of the different metabolite profiles between the two administration procedures, the inhibitory effects of plasma A, HPLC profiles of quercetin metabolites in rat plasma separated by using condition I described in the Materials and Methods section. Top, intragastric administration (50 mg/kg of body weight, 1 h); bottom, free access of 1% quercetin for 4 weeks (inset, for 2 weeks). Asterisks indicate the peaks of quercetin metabolites which were not detected in untreated rat plasma. As a comparison with authentic standards, Q3GA, quercetin aglycone (Q), and 3 0 -or 4 0 -methylated quercetin (Me-Q) were identified. Based on previous reports, other metabolite subclasses were speculated. GA, glucuronide; S, sulfate. A bold arrow indicates the expected retention time of Q3GA. Fraction X was a major fraction containing quercetin metabolites. The Y axis indicates the absorbance at 370 nm (arbitrary units, a.u.). B, Plasma concentrations of quercetin metabolites determined by the HPLC analysis. Samples were analyzed after being treated with -glucuronidase/sulfatase, and then detected as quercetin (nonmethylated metabolites) and methylated quercetin (methylated metabolites). Each values is presented as the mean AE S.E. (n ¼ 6). Total quercetin concentrations (non-methylated + methylated) and the ratio (methylated/non-methylated) are also indicated. extracts of rats from the two procedures on LDL oxidation were evaluated. As shown in Fig. 4 , as compared with the control plasma, the extract from intragastric administration completely inhibited LDL oxidation, whereas the inhibitory effect of the extract from free-access feeding was quite weak. In this experiment, copper-induced LDL oxidation in the absence of the plasma extract significantly increased the TBARS value (12.4 nmol/mg of LDL, data not shown), showing the basal antioxidative activity in the control plasma, in which ascorbic acid, tocopherols, and/or bilirubin might have contributed. The current results show that the intragastric administration of quercetin significantly increased the additional antioxidative activity toward the plasma constituents in vivo.
Which procedure was similar to the profile for human plasma?
Finally, to examine which administration procedure was similar to the metabolite profile for human plasma, we compared the HPLC profile of the rat plasma samples with that of human plasma samples after an intake of onion, a representative quercetin-containing vegetable. As shown in Fig. 5 and previously reported, 18) a number of quercetin metabolites including Q3GA were detected in human plasma after the intake of onion. The Q3GA concentration was 264 AE 46 nM (n ¼ 4).
18) The pattern was quite similar to that from the intragastric administration of quercetin to rats. These results suggest that an intragastric administration of quercetin, rather than free access, to rats might reflect the situation for the intake of quercetin by humans.
Discussion
We demonstrated in this study that the profiles for quercetin metabolites in rat plasma were quite different between the two administration procedures (intragastric and free access), and that this difference significantly affected the antioxidative potential of the plasma. The two administration procedures are widely used for animal experiments while feeding a compound(s) to rodents. In general, intragastric administration has been used for short-term examination to evaluate the acute response of a compound. In contrast, free access experiments are often used for evaluating the effect(s) of the chronic and long-term administration of a compound. Although many animal experiments using either procedure for quercetin administration have been reported, 12, 20, 23, 24) the different metabolite profiles that would affect the biological activities have not yet been reported, as far as we know. We have demonstrated here that the plasma from free access of quercetin contained highly conjugated metabolites (Fig. 2) . In particular, the extent of methylation was much higher than that with intragastric administration (Fig. 1) . Blockage of the catechol moiety, including methylation, glucuronidation, and sulfation, significantly decreases the antioxidative activity (Fig. 3 and ref. 10 ). Mass spectrometric analyses have shown that sulfo-glucuronide(s) of methylquercetin, in which three positions of the five hydroxyl groups of quercetin were conjugated, might have been the major metabolites in Fraction X of free-access plasma (Fig. 2) . The plasma extracts containing highly conjugated metabolites from the free-access group exhibited less effective antioxidative activity toward LDL oxidation in vitro than the intragastric group (Fig. 4) . These results show that the two widely used procedures for quercetin administration might result in different antioxidative potentials in the plasma. It has been reported that several tissues could be involved in the absorption and metabolism of quercetin. [25] [26] [27] It has also been reported that (i) the main conjugation reaction in rat intestinal mucosa is glucuronidation by uridine 5 0 -diphosphate glucuronosyltransferase, (ii) sulfation by sulfotransferase only takes place in the liver, and (iii) methylation by COMT mainly occurs in the liver and kidney. 27) Non-methylated metabolite Q3GA, a major metabolite in the intragastric plasma, could scarcely be detected in the free access plasma (Fig. 1) . In addition, approximately 79% of the metabolites in the free access plasma were methylated, whereas only 28% were in the intragastric plasma (Fig. 1) . Furthermore, the major metabolites in Fraction X from free access were all of sulfated form (Fig. 2) . These observations suggest that secondary metabolism in the liver and/or kidney might have been involved in the appearance of highly conjugated metabolites in the free access plasma. It has also been reported that the total concentration of metabolites in the plasma reached a maximum after 0.5-1 h when administered with propylene glycol, whereas it gradually increased over 8 h when administered without propylene Non-protein plasma extracts were dissolved in PBS (the same volume of starting plasma), incubated with LDL (0.2 mg/ml) in the presence of 10 mM Cu 2þ for 0-24 h, and then the TBARS formation was measured. The final concentrations of total quercetin were approximately 0 (control), 2.5 (intragastric), and 7.0 (free access) mM as measured in Fig. 1B . Each value is expressed as the average of duplicate experiments. glycol (i.e., with water). 28) In addition, the absorption efficiency of quercetin is generally thought to depend on its solubility in the diet. Base on these observations, we speculate that the administration of quercetin in propylene glycol may result in efficient, that is, acute absorption of quercetin in the gastrointestinal tract and may then allow quercetin and its metabolites to escape from further secondary conjugation. In contrast, relatively slower absorption during free access may permit quercetin to be highly/secondarily conjugated in the liver and/or kidney. Free access may result in continuous supplementation and accumulation of quercetin in the blood. In addition, the total intake of quercetin in free access (213 mg/d/rat) was much higher than that from a single intragastric intake (50 mg/kg = 10 mg/200 g of rat). Thus, there might be the possibility that a higher concentration of quercetin would induce phase-II detoxification enzyme activity in the liver and kidney. Similar results recently published 29) also support our experimental data for rats. The precise mechanism for the difference in the metabolite profiles between the two procedures remains unclear and therefore needs to be clarified in the future.
The research data for the bioavailability of quercetin in rats and other animals needs to be applied to that in humans. It should be noted that the metabolite profile of human plasma after the intake of onion (rich in quercetin glycosides) was similar to that of the intragastric administration of the quercetin aglycone in rat (Fig. 5) . A single administration of 2.3 mg/kg of quercetin equivalent in onion was used in this human study, suggesting that a single, high-dose intake of quercetin would result in similar metabolite profiles in the plasma of both humans and rats. However, whether a single, high-dose intake of quercetin (in onion) by humans would be plausible or not as a daily intake of quercetin remains unknown. A long-term examination of onion intake by humans is now in progress in our laboratory. It is generally known that the human diet contains quercetin and other flavonoids mainly in their glycosidic form. We have confirmed that an intragastric administration to rats of quercetin-3-glucoside (Q3G), the major glycosidic form in plants, resulted in a similar metabolite profile in the plasma to that of quercetin administration (Kawai, Y. et al., unpublished results). These observations suggest that, at least for a single intake, the intragastric administration of quercetin to rats might be a suitable model for mimicking human quercetin intake.
We have reported that quercetin metabolites in human plasma might contribute to antioxidative activity for the peroxidation of lipoproteins. 16) Thus, the intragastric administration of quercetin to rats might be a useful model for evaluating the antioxidative activity of quercetin metabolites. Indeed, we have found that an intragastric administration, but not free access, of quercetin reduced the stress-induced oxidative stress in tissues (Kawai, Y. et al., unpublished results). In other words, free access experiments might be useful for investigating the biological activities of quercetin independently of the plasma antioxidative activity (so-called ''beyond antioxidants''). Benito et al. have reported that the free access of quercetin, catechin, or dealcoholated red wine in rats in the absence of any pathological or of oxidative stress did not alter the oxidative susceptibility in the plasma. 30) On the other hand, it has also been reported that free access of quercetin inhibited the azoxymethane-induced colon carcinogenesis in rats. 31) We have also previously reported that free access of quercetin significantly attenuated the development of atherosclerosis in hypercholesterolemic rabbits, 12) although the metabolite profiles in rabbit plasma have not yet been examined. It has recently been reported that site-specific deconjugation of the metabolites might occur during inflammation in vivo, 18, 32, 33) indicating the possibility that the flavonoids might be biologically active even after inactivated by conjugation. Current results might provide information about the bioavailability of quercetin, not only when conducting animal experiments but also when investigating the endogenous dynamics of these flavonoids in humans. Plasma after the Intake of Quercetin. The metabolites were separated by using condition II as described in the Materials and Methods section. The Y axis indicates the absorbance at 370 nm (arbitrary units, a.u.). A, Rat plasma extract after intragastric (IG) administration of quercetin (50 mg/kg, 30 min). B, Human plasma extract after intake of onion (500 g, 1.5 h). Gray-filled peaks indicate quercetin-3-glucuronide (Q3GA), whose the retention time completely matched that of an authentic standard.
